Animal Models of Emerging Viral Infection

NIH Pandemic-Era Grants

Pandemic Era Grants

2023

↗ Live URL (may be dead)

Document text

Principal Investigator: Daniel S Chertow
Organization: CLINICAL CENTER
Fiscal Year: 2023
Funding agency: NIH Clinical Center

Project 1: We previously developed a NHP ICU model in healthy (uninfected) NHPs. We have extended this model to included supportive care of animals infected with E.coli or K. pneumoniae. Among K. pneumoniae 
infected animals, we have completed initial bacterial dose-response studies and are now proceeding with our first intervention trial with a host-targeted potential therapy.  Additionally, we have completed a 2-animal pilot study providing supportive critical care to NHPs infected with Ebola virus. This study was successfully implemented in the NIAID biosafety-level (BSL)-4 Integrated Research Facility (IRF) in Fredrick, MD and will subsequently be implemented in NIAID BSL-4 Rocky Mountain Laboratories in Hamilton, Montana.

Terms: <Animal Model><Animal Models and Related Studies><Animals><Antibiotic Agents><Antibiotic Drugs><Antibiotics><Approaches to prevention><Bacteremia><Clinical><Clinical Management><Critical Care><Critical Illness><Critically Ill><Diagnosis><Dose><Dysfunction><E coli><E. coli><EBOV><Ebola virus><Ebola-like Viruses><Escherichia coli><Failure><Functional disorder><Goals><Human><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Individual><Infection><Intensive Care Units><Intervention Trial><Interventional trial><K pneumoniae><K. pneumoniae><Klebsiella pneumoniae><Laboratories><Miscellaneous Antibiotic><Modeling><Modern Man><Molecular><Montana><NIAID><National Institute of Allergy and Infectious Disease><Organ><Pathogenesis><Phylogenetic Analysis><Phylogenetics><Physiologic><Physiological><Physiopathology><Pilot Projects><Prevention approach><Research><Sepsis><Supportive Therapy><Supportive care><Syndrome><Viral Diseases><Virus Diseases><animal care><bacteraemia><bacterial sepsis><blood infection><bloodstream infection><ebolavirus><improved><model of animal><pathophysiology><pilot study><research facility><response><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><viral infection><virus infection><virus-induced disease>